Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model
摘要:
Diacylglycerol acyltransferase (DGAT) is expressed abundantly in intestine, liver, and adipose tissues. DGAT1 is the crucial and rate-limiting enzyme that mediates the final step in triacylglycerol (TAG) resynthesis during dietary fat absorption. However, too much triacylglycerol (TAG) reserve will lead to genetic obesity (Hubert et al., 2000). DGAT1 knockout mice could survive and displayed a reduction in the postprandial rise of plasma TG, and increased sensitivity of insulin and leptin. Here we report the discovery and characterization of a novel selective DGAT1 inhibitor 29 to potentially treat obesity. Compound 29 showed lipid lowering effect in mouse lipid tolerance test (LTT) and also reduced body weight in DIO mice without observable liver damage. (C) 2018 Elsevier Ltd. All rights reserved.
The tridentate phosphine ligand 1,3,5-tris[(E)-(4-phospholano-2,6-diethyl)styryl]benzene (1) reacts with [AuCl(tht)] (tht = tetrahydrothiophene) independent of the stoichiometry employed with selective formation of a two-dimensional coordinationpolymer (ratio 1 : 1) with the gold(I) cations in a trigonal-planar [3 + 1] coordination geometry. Each of the three coordinating phosphine units originates
作者:Nicholas R. Wurtz、Brandon L. Parkhurst、Indawati DeLucca、Peter W. Glunz、Wen Jiang、Xiaojun Zhang、Daniel L. Cheney、Jeffrey M. Bozarth、Alan R. Rendina、Anzhi Wei、Tim Harper、Joseph M. Luettgen、Yiming Wu、Pancras C. Wong、Dietmar A. Seiffert、Ruth R. Wexler、E. Scott Priestley
DOI:10.1016/j.bmcl.2017.04.008
日期:2017.6
FactorVIIa (FVIIa) inhibitors have shown strong antithrombotic efficacy in preclinical thrombosis models with limited bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful due to the requirement of a basic P1 group to interact with Asp189 in the S1 binding pocket, limiting their membrane permeability. We have combined recently reported neutral P1 binding
MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
申请人:Priestley Eldon Scott
公开号:US20090281139A1
公开(公告)日:2009-11-12
The present invention relates generally to novel macrocycles of Formula (I):
or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, L, M, W, Z, R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, R
9
, and R
10
are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.